On March 18, 2025, the American College of Cardiology (ACC) released its first-ever Concise Clinical Guidance (CCG) document. It is intended to provide healthcare professionals with a streamlined approach to best practices and actionable strategies for managing patients. The inaugural CCG is focused on the Evaluation and Management of Cardiogenic Shock.

Cardiogenic shock is a life-threatening condition where the heart fails to pump sufficient blood and oxygen to the brain and other vital organs leading to hypotension. If not recognized and treated swiftly, it can result in severe consequences, including organ failure and brain injury. The mortality rates for cardiogenic shock are alarmingly high, with short-term mortality ranging from 30-40% and one-year mortality often exceeding 50%. This stark data underscores the significance of the CCG and the urgent need for comprehensive, effective management protocols.

This Guidelines Spotlight highlights the key insights from the consensus statement, which focuses on both the evaluation and management of CS. While this overview touches on the document's key points, a more detailed examination can be accessed through the summary located here or the full text located here.

Key Takeaways

The SUSPECT CS Mnemonic: 

The CCG introduces a novel mnemonic, "SUSPECT CS," designed to aid clinicians in quickly identifying and diagnosing cardiogenic shock. This mnemonic serves as a clinical decision support tool, highlighting the critical diagnostic criteria necessary to establish the diagnosis early.

The mnemonic incorporates both laboratory markers and clinical symptoms such as pulmonary edema, jugular venous distension, peripheral edema, and hypoperfusion.

Roadmap for Clinical Evaluation: 

The CCG delineates a structured, time-sensitive evaluation protocol to guide clinicians through the critical first 24 hours after the diagnosis of CS. This framework provides a comprehensive roadmap for the initial management, ensuring that time-sensitive interventions are executed in a precise, efficient manner. The first hour post-diagnosis focuses on stabilizing the patient with appropriate pharmacological agents, mechanical support, and invasive monitoring as needed. The 24-hour timeline ensures that clinicians reassess the patient’s clinical status and adjust interventions based on the evolving hemodynamic profile.

Invasive Hemodynamic Monitoring: 

Invasive hemodynamic monitoring plays a pivotal role in the management of CS, as it provides real-time insights into the patient's circulatory status. Pulmonary artery catheterization remains a key tool for assessing both left and right heart function, as well as for guiding therapy decisions such as:

  • Vasopressor titration
  • Temporary mechanical circulatory support (tMCS) escalation or weaning- The CCG highlights the need for such invasive monitoring, particularly in patients with refractory shock or those undergoing mechanical support, as it aids in tailoring therapy to the patient's unique hemodynamic profile. Although the data supporting the direct impact of early hemodynamic monitoring on reducing mortality is still limited, ongoing trials (such as those examining heart failure-related cardiogenic shock) aim to clarify its potential benefits.

Pharmacological and Mechanical Support: 

The CCG provides comprehensive recommendations for pharmacological therapies and mechanical circulatory support, both of which are integral to stabilizing patients with CS. Key pharmacologic agents include:

  • Vasopressors and Inotropes: To support blood pressure and improve myocardial contractility.
  • Diuretics: To manage fluid overload and relieve symptoms of pulmonary congestion.
  • Anticoagulation: When appropriate, to manage the risk of thromboembolic events associated with mechanical support devices like intra-aortic balloon pumps or left ventricular assist devices (LVADs).

The guidance emphasizes a stepwise approach to escalation of care, with temporary mechanical circulatory support (tMCS), such as the impella device or extracorporeal membrane oxygenation (ECMO), considered when pharmacological therapies fail to stabilize the patient.

Ongoing Monitoring and Reassessment: 

A core principle of the CCG is continuous monitoring and frequent reassessment throughout the patient's course of treatment. Clinicians are encouraged to regularly evaluate hemodynamic parameters, laboratory markers, and clinical signs to ensure that therapeutic interventions are appropriately adjusted. This approach allows clinicians to adapt to the patient’s changing needs, avoid potential complications, and optimize outcomes. The importance of regular reassessment is especially critical in the first 72 hours of care, when the risk of adverse events is highest.

Advanced Therapy Decision-Making: 

The CCG outlines a clear decision-making framework for determining patient eligibility for advanced therapies. This includes the evaluation of:

  • Heart recovery strategies, such as the use of heart transplant eligibility or ventricular assist devices (VADs) for long-term support.
  • Referral to specialized heart failure centers for patients with refractory cardiogenic shock who require advanced care, including those eligible for consideration for heart transplant or LVAD implantation. The document stresses that these decisions should be based on a combination of clinical judgment, patient preferences, and available resources.

Interdisciplinary Collaboration: 

The management of cardiogenic shock requires a multifaceted, team-based approach. The CCG underscores the necessity of collaboration across specialties, including cardiology, critical care, surgery, and nursing. Multidisciplinary teams have been shown to improve patient outcomes, particularly in the management of complex conditions like cardiogenic shock. Key roles within the team include intensivists, cardiologists, heart failure specialists, and perfusionists, all working in concert to ensure the timely and appropriate delivery of care.

Additionally, the guidelines suggest that patients who require higher acuity care should be transferred to Level 1 CS centers equipped with the necessary expertise and resources for managing complex cardiogenic shock cases. However, the authors note that there is currently no standardized classification system for these centers, similar to trauma systems of care, and this represents an area of ongoing discussion within the field.

Evidence Gaps & Future Research

The CCG highlights significant evidence gaps in the management of CS, particularly regarding the outcomes of patients transferred to specialized centers and the use of invasive monitoring in the early stages of shock. The document advocates for ongoing research to address these gaps, with the goal of improving clinical outcomes through more refined protocols and evidence-based interventions.


This guidance marks a step toward standardizing the management of cardiogenic shock, offering healthcare providers evidence-based tools for improving patient survival and quality of care in this high-risk population.

It is also important to note that ACC will showcase the Concise Clinical Guidance as part of a session at its Annual Scientific Session (ACC.25), which will be held from March 29 to 31, 2025, in Chicago, IL. This session, titled ACC’s Solutions Sets: Real-Time Support for the Frontline Cardiovascular Clinician, will formally introduce CCGs as a new clinical policy format for the ACC. The session will take place on Monday, March 31, at 11:30 am CT.

We hope you found this Guideline Spotlight informative. Also, don’t forget to check out our ACC.25 Conference Preview on Coronary Artery Disease located here and the rest of ACC’s guidelines located here!

Sign up for alerts and stay informed on the latest published guidelines and articles.

Copyright © 2025 Guideline Central, all rights reserved.